Oncology Clinical Trial Market Roche is actively conducting pivotal trials for novel therapies targeting advanced breast cancer, aiming to ...

Cobenfy, Bristol Myers Squibb’s once-promising schizophrenia drug, just failed its Phase III ARISE trial as an add-on therapy ...

After mid-day highlighted the issues posed by make-shift toilet blocks along Ram Mandir railway station road, WR removed all ...

Education Minister Dada Bhuse stated that under National Education Policy (NEP), 2020, the Union government has not made ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Microsatellite Stable ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high ...

Veravas, a leader in clinical diagnostics, today announced the general commercial availability of VeraBINDtm Tau, the first blood-based test designed to aid in the detection of Alzheimer's disease (AD ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...

Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 ...